Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia.

In healthy population, uric acid comprises the major component of 10-20% of renal stones. Extreme hiperuricaemia is seen in cancer patients with tumour lysis syndrome (TLS) which is classically associated with haematological malignancies with rapid tumour growth rates such as acute lymphoid leukaemia and high grade lymphomas. Primary melofibrosis (Agnogenic myeloid metaplasia-AMM) is a chronic myeloproliferative disease characterized by splenomegaly, a leukoerythroblastic blood picture, teardrop poikilocytosis and varying degrees of marrow fibrosis. Due to the increased extramedullary haematopoiesis, hiperuricemia may occur. However, TLS in patients with AMM is, according to the available literature, described just in one patient. In this paper we present a case of a 47-year-old male patient who was admitted to the hospital with symptoms of fatigue and small amount of urine, and clinical signs of plethora and enlarged spleen. The laboratory findings showed leuko-and erythrocytosis, increased levels of urea-BUN (32 mmol/l) and creatinine (766 mmol/l) as well as uric acid (920 mmol/l). The immediate abdominal ultrasound confirmed extreme splenomegaly, but also showed bilateral hydronephrosis of grade II-III with two stones in proximal part of right ureter and one in proximal part of left ureter as well as empty bladder. Stones were not seen on plain film. Since the patient was in complete anuria, with further rapid elevation of BUN and creatinine levels, bilateral ureteral stents were applicated together with extensive hydration, urine alkalization and administration of allopurinol which resulted in the complete recovery of kidney function. The bone marrow biopsy was also performed and histopathological diagnosis was: Hypercellulary phase of AMM.

[Urethral syndrome in men--chronic pelvic pain syndrome].

INTRODUCTION: Chronic pelvic pain syndrome (CPPS) is defined as pelvis minor pain of nonmalignant nature repeating in different time intervals. Urethral syndrome (US) represents a most poorly defined entity within CPPS. OBJECTIVE: The estimation of US influence on quality-of-life as well as the determination of the way of treatment and therapy optimal length. MATERIAL AND METHODS: A prospective one-year study included 166 men with CPPS, median age of 54 years; they were monitored clinically. During the patient monitoring the NIH-CPSI questionnaire (National Institute of Health-Chronic Prostatis Symptom Index) was used. US was diagnosed in 79 patients (47%), and according to the most intensive pain localization they were divided into three groups. All the patients were treated with alpha adrenergic blockers and non-steroidal anti-inflammatory drugs, and the treatment of the patients with positive urethral smear also included antibiotherapy. The values of total NIH-CPSI, as well as of its individual components were analyzed after three and six months of treatment. RESULTS AND DISCUSSION: The therapy application had a significant influence on the decrease of total NIH-CPSI--23.3% (p < 0.01), pain symptoms (p < 0.0) and urinary difficulties (p < 0.01), and the point values of quality-of-life score were diminished by 0.7 to 1.9 points depending on the group of those monitored (p < 0.01). CONCLUSION: Our study indicated a significant influence of CPPS on quality-of-life and a necessity of a serious approach to patients and their treatment.

[Late methylene blue appearance in urine after local treatment of cutaneous fistula in hip osteomyelitis as a first sign of renal failure].

Methylene blue is a dark green crystal. In medicine it is used as water or alcohol solution. Methaemoglobinemia, hypotension, septic shock are some of many diseases that are treated with methylene blue. In surgery methylene blue is used in diagnostic procedures such as a fistula detection or detection of the parathyroids glands, and for the delineation of certain body tissues during surgery. In patient with normal renal function methylene blue is appearing in urine in a few minutes after intravenous administration. In our patient who was 70-year-old we remarked interesting phenomena after we instillation methylene blue into the fistila channel during local treatment of hip osteomyelitis. Methylene blue appeared in urine two days after local treatment, coloring the urine light green and color elimination time was prolonged in few days. These parameters induced as to suspect in renal failure. That was prowed after urological, laboratory and radiology examination.